Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)

Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for levonorgestrel tablets, 0.75 mg, for women seventeen years and younger.
Continue Read…

This entry was posted in Medical News. Bookmark the permalink.

Leave a Reply